FDA Approved: ATZUMI — Original Application (Satsuma Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved ATZUMI (dihydroergotamine mesylate) from Satsuma Pharmaceuticals in NDA217901 for the acute treatment of migraine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ATZUMI (DIHYDROERGOTAMINE MESYLATE)

Snippet

ORIG AP for ATZUMI (DIHYDROERGOTAMINE MESYLATE)